Mechanistic Studies on the Stereoselectivity of FFAR1 Modulators

• Free fatty acid receptor 1 (FFAR1) is a potential therapeutic target for the treatment of type 2 diabetes (T2D). It has been validated that agonists targeting FFAR1 can achieve the initial therapeutic endpoints of T2D, and the epimer agonists (R,S) AM-8596 can activate FFAR1 differently, with one acting as a partial agonist and the other as a full agonist. Up to now, the origin of the stereoselectivity of FFAR1 agonists remains elusive. In this work, we used molecular simulation methods to elucidate the mechanism of the stereoselectivity of the FFAR1 agonists (R)-AM-8596 and (S)-AM-8596. We found that the full agonist (R)-AM-8596 disrupts the residue interaction network around the receptor binding pocket and promotes the opening of the binding site for the G-protein, thereby resulting in the full activation of FFAR1. In contrast, the partial agonist (S)-AM-8596 forms stable electrostatic interactions with FFAR1, which stabilizes the residue network and hinders the conformational transition of the receptor. Our work thus clarifies the selectivity and underlying molecular activation mechanism of FFAR1 agonists. 

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Endokrinologi och diabetes (hsv//swe)

MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Endocrinology and Diabetes (hsv//eng)

Nyckelord

Chemical activation

Fatty acids

Acid receptors

Epimers

Free fatty acid

Interaction networks

Mechanistic studies

Molecular simulations

Receptor binding

Receptor-1

Therapeutic targets

Type-2 diabetes

Stereoselectivity

FFAR1 protein

human

G protein coupled receptor

binding site

chemistry

human

non insulin dependent diabetes mellitus

Binding Sites

Diabetes Mellitus

Type 2

Humans

Receptors

G-Protein-Coupled

Publikations- och innehållstyp

ref (ämneskategori)

art (ämneskategori)